Enveric BiosciencesFRA:SLZ0 30 PB Ratio is 24.18 as of Jul. 11, 2026. GuruFocus rates FRA:SLZ0 with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,227 Biotechnology companies, Enveric Biosciences ranks better than 94.38% on this metric.
The historical rank and industry rank for Enveric Biosciences's PB Ratio or its related term are showing as below:
FRA:SLZ0'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.53
Current: 0.53
During the past 13 years, Enveric Biosciences's highest PB Ratio was 0.53. The lowest was 0.00. And the median was 0.00.
FRA:SLZ0's PB Ratio is ranked better than 94.38% of 1227
companies
in the Biotechnology industry
Industry Median: 2.95
vs FRA:SLZ0: 0.53
During the past 12 months, Enveric Biosciences's average Book Value Per Share Growth Rate was -85.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -85.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -77.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Enveric Biosciences was -66.20% per year. The lowest was -85.20% per year. And the median was -82.90% per year.
Back to Basics: PB Ratio
Enveric Biosciences (FRA:SLZ0) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Enveric Biosciences PB Ratio Related Terms
Enveric Biosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Enveric Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Enveric Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enveric Biosciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enveric Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Enveric Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Enveric Biosciences (FRA:SLZ0) has a PB Ratio of 24.18 as of Jul. 11, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Enveric Biosciences and its competitors. According to the industry distribution chart, Enveric Biosciences ranks #69 out of 1227 companies in the Biotechnology industry, placing it in the top 5.6%.
Is Enveric Biosciences' PB Ratio too high?
Enveric Biosciences' current PB Ratio is 24.18. The Biotechnology industry median PB Ratio is 2.95. Enveric Biosciences' value of 24.18 is 719.7% above this industry median. Based on the distribution chart, Enveric Biosciences ranks #69 out of 1227 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Enveric Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Enveric Biosciences' PB Ratio compare to APVO and CNSP?
According to the Biotechnology industry distribution chart, Enveric Biosciences ranks #69 out of 1227 companies for PB Ratio. This places Enveric Biosciences in the top 6% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.95. Enveric Biosciences' value of 24.18 is 719.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enveric Biosciences's current PB Ratio of 24.18 is 719.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Enveric Biosciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enveric Biosciences's current PB Ratio is 24.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enveric Biosciences stock overvalued right now?
Enveric Biosciences (FRA:SLZ0) has a current PB Ratio of 24.18. The current PB Ratio is 24.18 and 719.7% above the Biotechnology industry median of 2.95. Enveric Biosciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Enveric Biosciences (FRA:SLZ0), the current PB Ratio is 24.18 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
30GF Score
Get the complete analysis for FRA:SLZ0
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:SLZ0 has been successfully added to your 
